Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DESF

Other · developed by Aquestive Therapeutics

Phase 2 Most advanced trial (none active)

AQST Developer

1 Registered trials

What is DESF?

DESF is administered in the sublingual space. It is studied in allergic reaction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Immunology
Developer: Aquestive Therapeutics (AQST)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06527937	Phase 2	Allergic Reaction	Completed	AQST

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic Reaction

Sources

ClinicalTrials.gov NCT06527937

Updated Oct 11, 2026. Something wrong or missing? Report it on the AQST page.

Follow AQST, the company behind DESF

See AQST's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AQST catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z